REACT-AF Trial: Rhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation

REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current standard of care of continuous DOAC use versus time-delimited (1 month) DOAC guided by an AF-sensing smart watch in participants with a history of non-permanent AF and low-to-moderate stroke risk (CHA₂DS₂-VASc score 1-5 for men, 2-5 for women). Follow-up time will be 3-5 years. The study will be conducted in up to 100 US centers targeting two-thirds academic and one-third private practices, with academic practices also enrolling from affiliated community sites.

Please visit the ClinicalTrials.gov page (NCT05836987) to learn more about the study, including the participation eligibility criteria.

See the participating clinical sites on the map below. For further site details, visit ClinicalTrials.gov – Contacts and Locations.

Tap the button and allow location sharing to view the map around your current location.